Nearly 4,000 bottles of blood pressure medicine recalled in the US

Nearly 4,000 bottles of blood pressure medicine recalled in the US

Nearly 4,000 bottles of blood pressure medicine recalled in the US

The US Food and Drug Administration has classified a nationwide recall of 3,744 bottles of a combination blood pressure medicine as Class II, meaning use of the product may cause temporary or reversible health effects. The medicine, a generic version of Tribenzor made by Macleods Pharma USA, combines olmesartan, amlodipine and hydrochlorothiazide. The company began the voluntary recall on October 7 after the tablets failed dissolution tests, which check how a pill breaks down in the body, and the FDA classified it on October 26. The recall covers 3,528 bottles of 30 tablets and 216 bottles of 90 tablets, all expiring on May 31, 2027. Patients are being urged to check their bottle's lot number and speak to a pharmacist if it matches.

The US Food and Drug Administration has classified a nationwide recall of 3,744 bottles of a combination blood pressure medicine as Class II, meaning use of the product may cause temporary or reversible health effects. The medicine, a generic version of Tribenzor made by Macleods Pharma USA, combines olmesartan, amlodipine and hydrochlorothiazide. The company began the voluntary recall on October 7 after the tablets failed dissolution tests, which check how a pill breaks down in the body, and the FDA classified it on October 26. The recall covers 3,528 bottles of 30 tablets and 216 bottles of 90 tablets, all expiring on May 31, 2027. Patients are being urged to check their bottle's lot number and speak to a pharmacist if it matches.

The US Food and Drug Administration has classified a nationwide recall of 3,744 bottles of a combination blood pressure medicine as Class II, meaning use of the product may cause temporary or reversible health effects. The medicine, a generic version of Tribenzor made by Macleods Pharma USA, combines olmesartan, amlodipine and hydrochlorothiazide. The company began the voluntary recall on October 7 after the tablets failed dissolution tests, which check how a pill breaks down in the body, and the FDA classified it on October 26. The recall covers 3,528 bottles of 30 tablets and 216 bottles of 90 tablets, all expiring on May 31, 2027. Patients are being urged to check their bottle's lot number and speak to a pharmacist if it matches.